New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer

Frontiers in Molecular Biosciences

Molecular Biosciences

Hongjian Yang¹  Xiping Zhang¹  Qiuhui Yang²  Yeqin Fu² 

[1] Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China;Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China;Wenzhou Medical University, Wenzhou, Zhejiang, China;

关键词: triple negative breast cancer;    miRNA;    diagnosis;    prognosis;    drug resistance;   

DOI  :  10.3389/fmolb.2023.1162463

 received in 2023-02-09, accepted in 2023-03-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Triple negative breast cancer is distinguished by its high malignancy, aggressive invasion, rapid progression, easy recurrence, and distant metastases. Additionally, it has a poor prognosis, a high mortality, and is unresponsive to conventional endocrine and targeted therapy, making it a challenging problem for breast cancer treatment and a hotspot for scientific research. Recent research has revealed that certain miRNA can directly or indirectly affect the occurrence, progress and recurrence of TNBC. Their expression levels have a significant impact on TNBC diagnosis, treatment and prognosis. Some miRNAs can serve as biomarkers for TNBC diagnosis and prognosis. This article summarizes the progress of miRNA research in TNBC, discusses their roles in the occurrence, invasion, metastasis, prognosis, and chemotherapy of TNBC, and proposes a treatment strategy for TNBC by interfering with miRNA expression levels.

【 授权许可】

Unknown   
Copyright © 2023 Fu, Yang, Yang and Zhang.